Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.

Higher protein intake may be protective against muscle loss, which is tied to less improvement in glucose homeostasis.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

A new report from The Center for Medicine in the Public Interest (CMPI) warns that regulators are failing to stop the illegal ...

The weight-loss drug Ozempic is linked to dry mouth bad breath and other oral issues Here’s what the expert says about ...

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

A MOTHER who put her daughter on weight loss jabs at the age of 11 has opened up on her family’s experience with the ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...